Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCI
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
Both pre- and postconditioning seem to protect cardiomyocytes during reperfusion therapy.
Investigations both ex vivo and in vivo suggest that a gut derived hormone,
Glucagon-Like-Peptide-1 (GLP-1), is able to reduce reperfusioninjury after myocardial
ischemia. Results from our own laboratory have shown a marked reduction in infarct size when
rat hearts in a Langendorf preparation were exposed to the GLP-1 analogue, exendin-4. The
investigators want to investigate to what extent this effect can be translated to humans in
the setting of acute STEMI treated with primary PCI when evalutaed by cardiac magnetic
resonance imaging.